Piers Morgan calls Dr Hilary 'Scrooge' after he reveals glaring issues with coronavirus vaccine on Good Morning Britain
PIERS Morgan branded Dr Hilary Jones "Scrooge" for pointing out glaring issues with the new coronavirus vaccine.
Show host Piers, 55, compared the medic to cold-hearted Ebenezer Scrooge from Charles Dickens' 1843 novel A Christmas Carol after he listed off a string of problems with the new Pfizer vaccine.
⚠️ Read our coronavirus live blog for the latest news & updates
Last night Boris Johnson announced the UK has stockpiled 40 million doses of the first Covid-19 jab – which requires two shots to work.
However, Dr Hilary, 67, said today: "It's not going to eradicate this virus from the face of the earth and I'll tell you why.
"Supply is going to be a real problem, it has to be stored at minus 70 to minus 80 degrees which creates problems in its own right, therefore it has to be used within five days of being delivered."
"Also we need billions of doses because we need it twice to cover the whole world, and we don't know if it stops transmission of the virus.
"We don't know if it works effectively in elderly, we don't know how long immunity will last."
He added: "But it is a major step in the right direction and the scientists who created it need a massive pat on the back.
"I've got to stress we can't got out and say 'hey we've got the vaccine this is a reason to rave and party' – that is not the case.
"We have to still be cautious."
Looking for some good news, Piers later asked him: "Will cancer patients be able to have this or will (their) low immune system make (them) not eligible?"
And Dr Hilary replied: "That's a good question I think the trials will have to be extended to incorporate those type of patients."
Pfizer revealed yesterday that its jab was proven to be 90 per cent effective at preventing Covid – on what experts hailed a "great day for humanity".
It took just ten months for the Pfizer vaccine to be developed.
In contrast, a traditional jab would take between ten to 15 years to develop.
Drug regulators must now wait for safety data out later this month before they can grant emergency approval for widespread use.
Source: Read Full Article